Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope
about
Inhibitory antibodies targeting emerging viruses: advancements and mechanismsDengue: an update on treatment options18F-FDG as an inflammation biomarker for imaging dengue virus infection and treatment responseSuppressive effect of dengue virus envelope protein domain III on megakaryopoiesis.Current Status of Dengue Therapeutics Research and Development.Hypoxia enhances antibody-dependent dengue virus infectionComprehensive mapping of functional epitopes on dengue virus glycoprotein E DIII for binding to broadly neutralizing antibodies 4E11 and 4E5A by phage display.Computational design of an epitope-specific Keap1 binding antibody using hotspot residues grafting and CDR loop swapping.Key concepts, strategies, and challenges in dengue vaccine development: an opportunity for sub-unit candidates?The impact of structural biology in medicine illustrated with four case studies.New developments in flavivirus drug discovery.Molecular basis of antibody-mediated neutralization and protection against flavivirus.The mechanistic role of antibodies to dengue virus in protection and disease pathogenesis.AChiralPentagonalPolyhedralFramework forCharacterizingVirusCapsidStructures.Antimicrobials: Novel antibodies defeat dengue virus.Antiviral drugs: Novel antibodies defeat dengue virus.Exploring the Immunopathogenesis of Viral Hemorrhagic Fever in Mice with a Humanized Immune System.Antibody therapies for the prevention and treatment of viral infections.A potent neutralizing antibody with therapeutic potential against all four serotypes of dengue virus.Dengue virus causes changes of MicroRNA-genes regulatory network revealing potential targets for antiviral drugs.A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.The use of databases, data mining and immunoinformatics in vaccinology: where are we?Development of envelope protein antigens to serologically differentiate Zika from dengue virus infection.Development of Antibody Therapeutics against Flaviviruses.Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein.Rational Engineering and Characterization of an mAb that Neutralizes Zika Virus by Targeting a Mutationally Constrained Quaternary Epitope.The use of humanized mice for studies of viral pathogenesis and immunity.Molecular basis for dengue virus broad cross-neutralization by humanized monoclonal antibody 513.Dengue virus non-structural protein 1: a pathogenic factor, therapeutic target, and vaccine candidateEngineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice
P2860
Q24289645-54686645-3DA4-4DC2-AB92-21BC0035821DQ28085044-9D6047A9-E94A-421A-AD77-7667F46EC1C1Q30250993-20629D6D-991B-4878-9F32-C5E8539F96DEQ33442742-696095F7-D410-45FB-AADA-ADB22D322F32Q33552896-B5813EAD-E4C5-49FF-92C4-AF7635181CF5Q33679954-9B4334F2-B03A-4240-B03E-D0CE7EAB30FEQ35764445-EEE00963-E86D-4BE2-AACA-CDED16DE5FB0Q37609410-1BD4A3AA-66DB-45E0-9319-99370127B78CQ38618056-2FB604B5-8016-4C06-AF98-8A51C9F9C1A0Q38698199-C75723DE-2CED-4E68-9A49-CA352845C649Q38769771-F707A509-5488-4074-9EE5-701109C51B76Q38948606-CD6DB27D-D7AB-415C-A9E6-C714C70FD552Q38994574-394C3542-518E-42FD-9B16-0C1985D3A791Q39017347-B860B944-D34D-4AD9-8992-1A67BD33F24FQ40143286-BE36B9DF-9130-489C-A41A-D6B00EF33368Q40143293-99C74E8C-F690-45C7-9928-29A22652A406Q41919588-F4AC00EA-11AE-412F-B000-1D7B69ECAC81Q47143843-EFAA46BA-2742-4134-B578-F4EF365912A3Q47156413-F7D3C208-E5B4-4718-A1D7-77B835C5B3C7Q47165163-F0C619A2-F21C-413E-8E3F-A1F142B45D4EQ47194469-FEFB3285-B2BB-442B-9E2B-80A1007FC3EBQ47262746-37C4632E-FD76-46BE-A18C-09F6E3F4666BQ47269331-CFD45BDE-633B-490B-BDB5-80231B3D592BQ47558158-BCE8B40C-93AE-410D-BABC-2C0A4B1934ACQ50099498-B9E4B519-CB8C-4C3B-9A59-F3ACCB1C8DADQ54215484-5696AD2D-ECAF-495B-8B39-B9EE0E9A0501Q54244413-40ABD0FA-EC97-4835-BCB2-CF0D3CE12421Q55363151-B4B69005-6D6E-4F9D-B2B9-07C19793D635Q56396121-DEF3148C-6DED-49B5-B6A5-2C907D0B9329Q56888687-25253E02-07E3-4D85-BA43-AE23DC682BA3
P2860
Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope
description
2015 nî lūn-bûn
@nan
2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Structure-Guided Design of an ...... o a Non-immunodominant Epitope
@ast
Structure-Guided Design of an ...... o a Non-immunodominant Epitope
@en
Structure-Guided Design of an ...... o a Non-immunodominant Epitope
@nl
type
label
Structure-Guided Design of an ...... o a Non-immunodominant Epitope
@ast
Structure-Guided Design of an ...... o a Non-immunodominant Epitope
@en
Structure-Guided Design of an ...... o a Non-immunodominant Epitope
@nl
prefLabel
Structure-Guided Design of an ...... o a Non-immunodominant Epitope
@ast
Structure-Guided Design of an ...... o a Non-immunodominant Epitope
@en
Structure-Guided Design of an ...... o a Non-immunodominant Epitope
@nl
P2093
P2860
P50
P1433
P1476
Structure-Guided Design of an ...... o a Non-immunodominant Epitope
@en
P2093
Boopathy Ramakrishnan
Chong Wai Liew
David Cain
Gregory J Babcock
Hamid Tissire
Hwee Cheng Tan
James R Myette
Jianzhu Chen
Kannan Tharakaraman
Karthik Viswanathan
P2860
P304
P356
10.1016/J.CELL.2015.06.057
P407
P577
2015-07-30T00:00:00Z